A great advance in the prevention of CVD has resulted from the identification of measurable
factors that predict the development of CVD. These factors are termed risk factors. Several …

Although graft and patient survival after solid organ transplantation have improved markedly
in recent years, transplant recipients continue to experience an increased prevalence of …

As obesity rates increase, so too do the risks of type 2 diabetes, cardiovascular disease, and
numerous other detrimental conditions. The prevalence of obesity in US adults more than …

Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a
sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed …

Background A recent meta-analysis raised concern regarding an increased risk of myocardial
infarction and death from cardiovascular causes associated with rosiglitazone treatment of …

… was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean
weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the …

… P. Home has received consultancy fees and/or honoraria from Novo Nordisk and sanofi
aventis. J. Rosenstock has served on advisory boards and received honoraria/consulting fees …

There is now extensive evidence on the optimal management of diabetes, offering the
opportunity of improving the immediate and long-term quality of life of those with diabetes. …

OBJECTIVE To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300)
with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥…

… One participant in the lixisenatide group died suddenly at home on day 25. This event was
assessed at autopsy as sudden cardiac death and deemed not to be treatment related by the …